Abstract: Devices, systems, and techniques for therapy delivery and healthcare management is described. In one example, a system comprises a delivery device configured to execute therapy information comprising a treatment schedule specifying one or more treatments over a time period, wherein for each of the one or more treatments, the therapy information comprises a treatment type and a treatment amount; and processing circuitry configured to: determine a modification to the therapy information based on a recommendation of a digital twin, wherein the digital twin determines an estimated glucose level expected to be within a healthy range if the delivery device executes the modification to therapy information; and in response to physician review of the modification to the therapy information, output, to a healthcare provider system for the patient, data indicating completion of a healthcare service corresponding to the physician review.

Abstract: A bitter masking agent includes a biochelant and a salt. A composition for an additive to reduce bitterness includes a chelant sodium salt including an aldonic, uronic, or aldaric acid. The bitter masking agent or additive comprising the biochelant and the salt can be combined with an edible material to reduce the bitterness thereof.

Abstract: Provided herein are methods and compositions for preparing nucleic acids in samples that preserve spatial-proximal contiguity information. Samples include, but are not limited to, formalin-fixed paraffin-embedded (FFPE) samples, deeply formalin-fixed samples and samples that comprise protein:cfDNA complexes.

Abstract: Provided herein are methods and compositions for preparing nucleic acids in samples that preserve spatial-proximal contiguity information. Samples include, but are not limited to, formalin-fixed paraffin-embedded (FFPE) samples, deeply formalin-fixed samples and samples that comprise protein:cfDNA complexes.

Abstract: Devices, systems, and techniques for therapy delivery and healthcare management is described. In one example, a system comprises a delivery device configured to execute therapy information comprising a treatment schedule specifying one or more treatments over a time period, wherein for each of the one or more treatments, the therapy information comprises a treatment type and a treatment amount; and processing circuitry configured to: determine a modification to the therapy information based on a recommendation of a digital twin, wherein the digital twin determines an estimated glucose level expected to be within a healthy range if the delivery device executes the modification to therapy information; and in response to physician review of the modification to the therapy information, output, to a healthcare provider system for the patient, data indicating completion of a healthcare service corresponding to the physician review.

Abstract: Provided herein are methods and compositions for preparing nucleic acids in samples that preserve spatial-proximal contiguity information. Samples include, but are not limited to, formalin-fixed paraffin-embedded (FFPE) samples, deeply formalin-fixed samples and samples that comprise protein:cfDNA complexes.

Abstract: Systems and methods are provided wherein intracardiac electrogram (IEGM) signals are used to determine a set of preliminary optimized atrioventricular (AV/PV) and interventricular (VV) pacing delays. In one example, the preliminary optimized AV/VV pacing delays are used as a starting point for further optimization based on impedance signals such as impedance signals detected between a superior vena cava (SVC) coil electrode and a device housing electrode, which are influenced by changes in stroke volume within the patient. Ventricular pacing is thereafter delivered using the AV/VV pacing delays optimized via impedance. In another example, parameters derived from IEGM signals are used to limit the scope of an impedance-based optimization search to reduce the number of pacing tests needed during impedance-based optimization. Biventricular and multi-site left ventricular (MSLV) examples are described.

Abstract: Systems and methods are provided wherein intracardiac electrogram (IEGM) signals are used to determine a set of preliminary optimized atrioventricular (AV/PV) and interventricular (VV) pacing delays. In one example, the preliminary optimized AV/VV pacing delays are used as a starting point for further optimization based on impedance signals such as impedance signals detected between a superior vena cava (SVC) coil electrode and a device housing electrode, which are influenced by changes in stroke volume within the patient. Ventricular pacing is thereafter delivered using the AV/VV pacing delays optimized via impedance. In another example, parameters derived from IEGM signals are used to limit the scope of an impedance-based optimization search to reduce the number of pacing tests needed during impedance-based optimization. Biventricular and multi-site left ventricular (MSLV) examples are described.